Definium Therapeutics Launches 'Wired for Worry' Initiative to Advance GAD Education for Healthcare Providers
Key Insights
Definium Therapeutics (search) launched Wired for Worry, a healthcare provider education initiative focused on generalized anxiety disorder (search), which affects approximately 26 million U.S. adults.
The platform provides evidence-based resources on GAD symptoms, neurobiology, and the dysregulated brain circuitry underlying chronic symptoms and functional impairment.
The initiative emphasizes consistent use of the GAD-7 screening scale to improve patient identification and outcomes, addressing high rates of pharmacotherapy switching and care gaps.
Definium Therapeutics (search), Inc., a late-stage clinical biopharmaceutical company focused on developing next-generation therapeutics for psychiatric and neurological disorders, today announced the launch of Wired for Worry, a new healthcare provider disease education initiative centered on generalized anxiety disorder (search) (GAD). The initiative arrives at a time when GAD affects approximately 26 million U.S. adults and treatment innovation has remained stagnant for nearly two decades.
The platform, accessible at www.WiredforWorry.com, delivers interactive clinical resources and evidence-based educational content covering GAD symptoms, assessment, disease burden, and underlying neurobiology. It is designed to equip healthcare professionals with a deeper understanding of a disorder that, when left untreated, can cause chronic, pervasive, and debilitating symptoms.
"The mental health providers who care for the millions of people living with GAD deserve more support," said Dan Karlin, MD, Chief Medical Officer of Definium Therapeutics (search). "Wired for Worry equips healthcare providers with the emerging science of the neural dysregulation underlying this disorder and increased knowledge of how patients' GAD symptoms can manifest well beyond excessive worry. A deeper understanding of disease-related information, including tools and resources for GAD assessment and management, is essential to advancing our knowledge of this complex disorder."
Addressing a Critical Gap in GAD Care
The Wired for Worry initiative responds to several pressing challenges in GAD management. Patients with GAD experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care, according to real-world evidence. The platform highlights how GAD may result from dysregulated brain circuitry that contributes to chronic symptoms and functional impairment, drawing on neuroimaging research that has identified structural and functional neural differences in individuals with the disorder.
A central component of the initiative is its emphasis on the Generalized Anxiety Disorder (search)-7 (GAD-7) screening scale. Consistent use of this validated tool can significantly improve patient identification and outcomes, as demonstrated in recent implementation research on measurement-based care.
The Burden of GAD
GAD is one of the most common psychiatric disorders in the United States. People living with the condition experience constant, overwhelming worry that is difficult to control, accompanied by symptoms including fatigue, muscle tension, trouble concentrating, and difficulty sleeping. The functional toll is substantial: patients report up to 10 days of limitations in daily and occupational responsibilities in a single month. Individuals with GAD also face an increased risk of suicidal ideation and behavior.
The disorder is associated with the development of other chronic physical illnesses, as well as depression, other anxiety disorders, and trauma-related conditions. These comorbidities contribute to substantial functional, economic, and quality-of-life burdens and are linked to increased healthcare utilization and costs.
A Stagnant Treatment Landscape
Despite the significant personal and societal burden of GAD, therapeutic innovation has been notably absent. The last new drug approval for the condition occurred in 2007, when the FDA approved duloxetine (Cymbalta) for the treatment of generalized anxiety disorder (search). This nearly two-decade gap underscores the unmet need that Definium Therapeutics (search) aims to address through its broader mission.
Definium, headquartered in New York and trading on Nasdaq under the symbol DFTX, is applying scientific rigor to psychedelics with the goal of developing accessible treatments that address the underlying causes of psychiatric and neurological disorders. The company plans to expand the Wired for Worry platform over time with additional educational content and resources for healthcare professionals, as well as materials covering other psychiatric disorders.